Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 17 von 35 | SupStack

Metformin – Forschungsarchiv

Studien 1751–1800 von 2685, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

1751Meta-Analyse2012

Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT · Breast Cancer Res Treat (2012)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Metformin and breast cancer risk: a meta-analysis and critical literature review.

The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis.

Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study.

The effect of metformin on insulin resistance and exercise parameters in patients with heart failure.

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.

Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial.

Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis.

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.

Quantifying the effect of metformin treatment and dose on glycemic control.

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.

The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.

A clinical trial to maintain glycemic control in youth with type 2 diabetes.

Metformin's effect on first-year weight gain: a follow-up study.

Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.

β-cell function preservation after 3.5 years of intensive diabetes therapy.

Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.

Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.

On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis.

Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.

Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome.

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.

Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose.

Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study.

Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.

Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.

Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis.

Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes.

Comparison of metformin and insulin in the control of hyperglycaemia in non-diabetic critically ill patients.

Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero.

Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Metformin versus lifestyle changes in treating women with polycystic ovary syndrome.

The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial.

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.

[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].

Predictive value of HbA1c for incident diabetes among subjects with impaired glucose tolerance--analysis of the Indian Diabetes Prevention Programmes.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Lifestyle intervention improves fitness independent of metformin in obese adolescents.

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.